Health risks for young adults increase with even a slight decline in kidney function.

Published Date: 26 Jun 2023

Even a slight decline in kidney function is linked to better health, according to a study of more than 8 million adults in Ontario, Canada.

Read Full News

Latest News

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

Closing Gaps in IgA Nephropathy Diagnosis and Treatment, With Brad Rovin, MD Brad Rovin, MD

Brad Rovin, MD, discusses gaps in IgA nephropathy care, biopsy's expanding role, and how new B cell therapies are reshaping treatment.

What's Still Missing in IgA Nephropathy Care, With Brad Rovin, MD Brad Rovin, MD

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

Bioengineered Vessel Increases Catheter-Free Time in Women on Dialysis Mohamad Hussain, MD, PhD

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

Brad Rovin, MD, discusses gaps in IgA nephropathy care, biopsy's expanding role, and how new B cell therapies are reshaping treatment.

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

News All Time

For Incarcerated Patients, Kidney Care Can't Wait, With Laura Maursetter, MD Laura Maursetter, MD

A nephrologist outlines gaps in CKD tracking, medication access, and transplant standards across the carceral health system.

Pacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial Abigail Brooks, MA

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

New ESC, ERA Guideline Calls for Universal CKD Screening in Cardiovascular Disease Abigail Brooks, MA

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

Diagnosis to Data: What Patient Experience Adds to IgAN Research Bryon Wade

A principal healthcare consultant and study co-author shares his own decade-long path to an IgA nephropathy diagnosis and transplant.

Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data Alex Hillenbrand

Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.

FAQ: Understanding New ESC/ERA Guideline on Cardiovascular Disease and Chronic Kidney Disease Patrick Campbell

ESC and ERA issue the first dedicated guideline on managing cardiovascular disease alongside chronic kidney disease, via a “STAMP on CKD” framework.

Kidney Organoids May Speed AKI Drug Screening, With Alexander Combes, PhD Alexander Combes, PhD

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD Abigail Brooks, MA

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care George Vasquez-Rios, MD

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Inaxaplin Cuts Proteinuria in Broader APOL1 Kidney Disease Population Alex Hillenbrand

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

Nearly 9 in 10 US Adults With CKD Don't Know They Have It, With Pranav Garimella

Nearly 9 in 10 US Adults With CKD Don't Know They Have It, With Pranav Garimella

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

Pediatric Acute Kidney Injury Cases Increased Tenfold Over Past 25 Years

— In-hospital mortality among pediatric patients with AKI improved, however

Kidney Transplant Disparities Persist With Intellectual, Developmental Disability

— Study suggests little impact from states' anti-discrimination laws

Recommended News For You

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Race, Geography Linked to Gaps in Prostate Cancer Care

Novel probes to label macrophages associated with cancer progression using a selective dye

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Time to Rethink Maintenance Pemetrexed in NSCLC?

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Circulating Tumor DNA Dynamics for Therapy Matching: A Comprehensive Clinical Review 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Screening for Early Changes in Blood-Cell Production Capacity in Older Adults 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

AVD Chemo Regimen Shows Promise in Older Patients With HL

3.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

4.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

5.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

1.

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations

2.

Contemporary Insights in Oncology in the Digital Era

3.

Strategic Concepts in Hematology for Modern Medicine

4.

Ferroptosis-Modulating Therapeutics in Precision Oncology

5.

Exploring the Potential of Bendamustine in Cancer Treatment

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

2.

Blood Clotting Disorders Explained

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

Chemotherapy: What to Expect

5.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot